Skip to main content

Table 1 Summary of the key epidemiological characteristics of the studies selected

From: High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis

Reference Country Total patients (% of women) Mean age (SD) Scale assessing depression Scale assessing migraine
Maasumi et al. [20] USA 359 (86.1%) 45.1 (13.2) PHQ-9 HIT6
Boudreau et al. [21] Canada 32 (87.5%) 42.4 (12.4) PHQ-9, BDI-II HIT6, MIDAS, VAS
Kollewe et al. [22] Germany 27 (92.3%) 45.6 (10.8) BDI HIT6
Russo et al. [19] Italy 52 (88.5%) 48.7 (12.9) BDI-II MIDAS
Demiryurek et al. [23] Turkey 60 (73.3%) 34.7 (6.4) BDI MIDAS, VAS
Guerzoni et al. [24] Italy 57 (80.7%) 54.2 (13) Zung-D HIT6, VAS
Aydinlar et al. [18] Turkey 190 (87.9%) 39.3 (10.2) DASS-21 MIDAS
Blumenfeld et al. [25] USA 715 (84.8%) 43.0 (11.3) PHQ-9 None